<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04443608</url>
  </required_header>
  <id_info>
    <org_study_id>CRA-US-001</org_study_id>
    <nct_id>NCT04443608</nct_id>
  </id_info>
  <brief_title>Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management</brief_title>
  <acronym>PLATINUM</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 4 Study of the Efficacy &amp; Safety of Patiromer for Oral Suspension in Combination With Standard of Care Treatment in ED Patients With Hyperkalemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Comprehensive Research Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Comprehensive Research Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      When a patient arrives to an emergency department and is found to have an elevated potassium&#xD;
      level in the blood, there is no one standardized treatment, therefore it is not known if one&#xD;
      treatment is superior to other. The purpose of this study is to help determine if a drug&#xD;
      called patiromer (already approved by the FDA) can help lower potassium levels while patients&#xD;
      are in the emergency department.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Given the lack of consistency in hyperkalemia treatment in the ED and the high cost of&#xD;
      emergent dialysis, there is a need for the development and systematic evaluation of a&#xD;
      treatment protocol to shift potassium into the cells followed by the removal of potassium&#xD;
      from the body with a potassium binder.. The present study will use a systematic approach to&#xD;
      shifting potassium into the cells followed by binding potassium in the gastrointestinal tract&#xD;
      in hyperkalemic patients presenting to the ED. Study subjects will receive patiromer or&#xD;
      placebo to determine if patiromer reduces the need for additional medical intervention for&#xD;
      the management of hyperkalemia in patients initially treated with IV and inhaled therapy in&#xD;
      the ED.&#xD;
&#xD;
      Upon enrollment, patiromer will be administered at a dose selected because of its safety and&#xD;
      efficacy shown in a pilot study named REDUCE.&#xD;
&#xD;
      Up to 300 patients will be enrolled and followed for up to 14 days, and potassium levels will&#xD;
      be measured at pre-determined intervals to assess drug's impact. concomitant medications will&#xD;
      be recorded to help determine if study drug helped, not just lower hyperkalemia, but also&#xD;
      decrease the number of total interventions needed to reach a normal potassium level.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">August 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blinded, placebo-controlled parallel group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The need for additional potassium-lowering medical interventions</measure>
    <time_frame>Duration of patient's emergency department visit, up to 10 hours</time_frame>
    <description>Number of potassium-lowering therapeutic interventions administered after study drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potassium level trends after receiving study drug</measure>
    <time_frame>Up to 24 hours after study drug dose is given</time_frame>
    <description>Potassium levels measured at hour 0, 2, 4, 6, 8, 10 and 24 hours after study drug administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Veltassa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 packets of study drug powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink while in the emergency department</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patiromer Powder for Oral Suspension [Veltassa]</intervention_name>
    <description>Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink</description>
    <arm_group_label>Veltassa</arm_group_label>
    <other_name>Active drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Inactive substance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hyperkalemia, defined as K+ ≥5.8 obtained via local laboratory or point-of-care&#xD;
             testing&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant arrhythmia, defined as any arrhythmia requiring ongoing IV&#xD;
             antiarrhythmic therapy.&#xD;
&#xD;
          2. Patients who are hemodynamically unstable, defined as mean arterial pressure ≤65 mmHg&#xD;
             or heart rate ≤40 beats per minute or ≥125 beats per minute at time of screening&#xD;
&#xD;
          3. Hyperkalemia solely due to overdose on potassium supplements&#xD;
&#xD;
          4. Known bowel obstruction&#xD;
&#xD;
          5. Subjects currently being treated with or having taken potassium binders (e.g.,&#xD;
             patiromer, sodium or calcium polystyrene sulfonate or sodium zirconium cyclosilicate)&#xD;
             in the 7 days prior to baseline&#xD;
&#xD;
          6. Subjects expected to receive dialysis during the first 6 hours of the study treatment&#xD;
             period&#xD;
&#xD;
          7. Known hypersensitivity to patiromer or its ingredients&#xD;
&#xD;
          8. Participation in any other investigational device or drug study &lt;30 days prior to&#xD;
             screening, or current treatment with other investigational agent(s)&#xD;
&#xD;
          9. Inability to consume the investigational product or, in the opinion of the&#xD;
             Investigator unsuitable for study participation&#xD;
&#xD;
         10. Life expectancy of less than 6 months&#xD;
&#xD;
         11. Patients with automatically timed medication orders to control potassium in the ED&#xD;
&#xD;
         12. Patient is known to be pregnant or breastfeeding&#xD;
&#xD;
         13. An employee of investigational site or sponsors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosen Mann</last_name>
      <phone>408-460-5885</phone>
      <email>rka@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Youyou Duanmu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Malicki</last_name>
      <phone>203-737-6152</phone>
      <email>caitlin.malicki@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Basmah Safdar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abe Lovelace</last_name>
      <phone>313-745-6492</phone>
      <email>ef2030@wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Lagina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hashem Nassereddine</last_name>
      <phone>313-404-9110</phone>
      <email>hnasser7@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Howard Klausner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin Healthcare Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Hendrickson</last_name>
      <phone>612-873-9528</phone>
      <email>Audrey.Hendrickson@hcmed.org</email>
    </contact>
    <investigator>
      <last_name>Brian Driver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University of St Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Mills</last_name>
      <phone>314-273-1382</phone>
      <email>jamiem@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Char, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Fernandes</last_name>
      <phone>631-444-7857</phone>
      <email>Rafael.Fernandes@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Kohler</last_name>
      <phone>336-716-4646</phone>
      <email>lekoehle@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Stopyra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Davis</last_name>
      <phone>513-558-5359</phone>
      <email>davis2jq@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Fermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University. Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Hill</last_name>
      <phone>614-293-6185</phone>
      <email>Michael.hill@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Bischof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JPS Health Network</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Max Masuda</last_name>
      <phone>817-702-6746</phone>
      <email>MMasuda@jpshealth.org</email>
    </contact>
    <investigator>
      <last_name>James d'Etienne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Keene</last_name>
      <phone>713-873-7042</phone>
      <email>Kelly.Keene@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Boone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>June 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>potassium</keyword>
  <keyword>dialysis</keyword>
  <keyword>emergency department</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

